Pilar Ballester M, Carbonell-Asins JA, Elshabrawi A, Rubin D, et al. A randomized, open-label, Phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis. Hepatology 2026 Apr 3. doi: 10.1097/HEP.0000000000001748.
PMID: 41931103